These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34536931)

  • 61. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.
    Huang B; Chen W; Zhao T; Li Z; Jiang X; Ginex T; Vílchez D; Luque FJ; Kang D; Gao P; Zhang J; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2019 Feb; 62(4):2083-2098. PubMed ID: 30721060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
    Tian Y; Du D; Rai D; Wang L; Liu H; Zhan P; De Clercq E; Pannecouque C; Liu X
    Bioorg Med Chem; 2014 Apr; 22(7):2052-9. PubMed ID: 24631361
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1.
    Yang Y; Pannecouque C; Clercq E; Zhuang C; Chen FE
    Bioorg Chem; 2020 Jun; 99():103825. PubMed ID: 32334191
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
    Jiang X; Huang B; Olotu FA; Li J; Kang D; Wang Z; De Clercq E; Soliman MES; Pannecouque C; Liu X; Zhan P
    Eur J Med Chem; 2021 Mar; 213():113051. PubMed ID: 33279288
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
    Wang Z; Yu Z; Kang D; Zhang J; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Bioorg Med Chem; 2019 Feb; 27(3):447-456. PubMed ID: 30606670
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.
    Frączek T; Kamiński R; Krakowiak A; Naessens E; Verhasselt B; Paneth P
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):9-16. PubMed ID: 29098886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-
    Yang Y; Kang D; Nguyen LA; Smithline ZB; Pannecouque C; Zhan P; Liu X; Steitz TA
    Elife; 2018 Jul; 7():. PubMed ID: 30044217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Gu SX; He QQ; Yang SQ; Ma XD; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Sep; 19(17):5117-24. PubMed ID: 21824782
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
    Xue P; Lu HH; Zhu YY; Ju XL; Pannecouque C; Zheng XJ; Liu GY; Zhang XL; Gu SX
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1640-1643. PubMed ID: 28314598
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
    Jin K; Sang Y; Han S; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2019 Aug; 176():11-20. PubMed ID: 31091477
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
    Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
    Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors.
    Ma XD; Yang SQ; Gu SX; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    ChemMedChem; 2011 Dec; 6(12):2225-32. PubMed ID: 21990112
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors.
    Li W; Huang B; Kang D; De Clercq E; Daelemans D; Pannecouque C; Zhan P; Liu X
    Chem Biol Drug Des; 2016 Sep; 88(3):380-5. PubMed ID: 27062197
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors.
    Liu Y; Meng G; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Pharm Sci; 2014 Oct; 62():334-41. PubMed ID: 24956462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.
    Jing L; Wu G; Zhao F; Jiang X; Liu N; Feng D; Sun Y; Zhang T; De Clercq E; Pannecouque C; Kang D; Liu X; Zhan P
    Eur J Med Chem; 2024 Nov; 277():116772. PubMed ID: 39167895
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yan ZH; Huang XY; Wu HQ; Chen WX; He QQ; Chen FE; De Clercq E; Pannecouque C
    Bioorg Med Chem; 2014 Apr; 22(8):2535-41. PubMed ID: 24680058
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
    Kang D; Zhang H; Wang Z; Zhao T; Ginex T; Luque FJ; Yang Y; Wu G; Feng D; Wei F; Zhang J; De Clercq E; Pannecouque C; Chen CH; Lee KH; Murugan NA; Steitz TA; Zhan P; Liu X
    J Med Chem; 2019 Feb; 62(3):1484-1501. PubMed ID: 30624934
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.
    Lei Y; Han S; Yang Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32111013
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
    Mao TQ; He QQ; Wan ZY; Chen WX; Chen FE; Tang GF; De Clercq E; Daelemans D; Pannecouque C
    Bioorg Med Chem; 2015 Jul; 23(13):3860-8. PubMed ID: 25907370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.